We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+9.38%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$5B
AUM Growth
-$515M
(-9.3%)
Cap. Flow
-$868M
Cap. Flow
% of AUM
-17.36%
Top 10 Holdings %
Top 10 Hldgs %
42.58%
Holding
90
New
18
Increased
21
Reduced
23
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAD
Rite Aid Corporation
RAD
|
+$221M |
| 2 |
Netflix
NFLX
|
+$154M |
| 3 |
AGN
Allergan Inc
AGN
|
+$138M |
| 4 |
Martin Marietta Materials
MLM
|
+$125M |
| 5 |
Vulcan Materials
VMC
|
+$121M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$439M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$401M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$230M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$155M |
| 5 |
Workday
WDAY
|
+$122M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.84% |
| 2 | Communication Services | 11.85% |
| 3 | Materials | 8.94% |
| 4 | Consumer Discretionary | 8.09% |
| 5 | Technology | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OCR
51
DELISTED
OMNICARE INC
OCR
| $17.9M | 0.36% |
269,298
+4,330
| +2% | +$269K |
|
|
IPXL
52
DELISTED
Impax Laboratories, Inc.
IPXL
| $16M | 0.32% |
+534,228
| New | +$14.4M |
|
53
Bruker
BRKR
$9.2B
| $15M | 0.3% |
616,620
-94,432
| -13% | -$2.05M |
|
|
ALDR
54
DELISTED
Alder Biopharmaceuticals
ALDR
| $14.8M | 0.3% |
+738,027
| New | +$10.4M |
|
|
RPRX
55
DELISTED
Repros Therapeutics Inc.
RPRX
| $14.7M | 0.29% |
850,942
-263,520
| -24% | -$4.3M |
|
|
MDCO
56
DELISTED
Medicines Co
MDCO
| $13.9M | 0.28% |
+476,934
| New | +$12.7M |
|
|
AEGR
57
DELISTED
Aegerion Pharmaceuticals
AEGR
| $10.8M | 0.22% |
+335,921
| New | +$12.5M |
|
|
ARAV
58
DELISTED
Aravive, Inc. Common Stock
ARAV
| $10.6M | 0.21% |
+62,905
| New | +$10.9M |
|
|
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
| $8.02M | 0.16% |
235,862
-85,041
| -27% | -$2.66M |
|
60
Viatris
VTRS
$20.1B
| $7.71M | 0.15% |
+149,532
| New | +$7.35M |
|
|
EIGR
61
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $6.37M | 0.13% |
883
+27
| +3% | +$135K |
|
|
RCPT
62
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $3.08M | 0.06% |
+72,283
| New | +$2.5M |
|
|
BLUE
63
DELISTED
bluebird bio
BLUE
| – | – |
-22,468
| Closed | -$6.62M |
|
|
64
Bristol-Myers Squibb
BMY
$127B
| – | – |
-7,722,083
| Closed | -$401M |
|
65
Cigna
CI
$76.6B
| – | – |
-169,613
| Closed | -$14.2M |
|
66
Salesforce
CRM
$134B
| – | – |
-949,774
| Closed | -$54.2M |
|
67
Cemex
CX
$17.4B
| – | – |
-524,747
| Closed | -$5.67M |
|
|
68
iShares MSCI Emerging Markets ETF
EEM
$28B
| – | – |
-10,702,700
| Closed | -$439M |
|
69
Expedia Group
EXPE
$31.2B
| – | – |
-484,412
| Closed | -$35.1M |
|
70
Liberty Global Class C
LBTYK
$3.27B
| – | – |
-2,162,273
| Closed | -$71.2M |
|
71
MacroGenics
MGNX
$235M
| – | – |
-209,212
| Closed | -$5.82M |
|
72
Myriad Genetics
MYGN
$530M
| – | – |
-40,491
| Closed | -$1.38M |
|
73
Pfizer
PFE
$140B
| – | – |
-1,272,050
| Closed | -$38.8M |
|
74
Prothena Corp
PRTA
$458M
| – | – |
-541,983
| Closed | -$20.8M |
|
75
Revvity
RVTY
$12.3B
| – | – |
-116,477
| Closed | -$5.25M |
|
Similar funds
DAM
MAM
LCM
PRS
DAM
KCM
CF
MIA
PFM Health Sciences's Q2 2014 Portfolio in Review
As of Q2 2014, PFM Health Sciences held 90 positions worth $5B, down 9.3% from $5.52B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
PFM Health Sciences withdrew a net $868M in Q2 2014, closing 27 positions and reducing 23 holdings. Its most notable exit was iShares MSCI Emerging Markets ETF, an estimated $439M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 46% a quarter earlier, followed by Communication Services and Materials.
Against the trend, PFM Health Sciences opened a new position in Netflix worth $179M.
- PFM Health Sciences's largest Q2 2014 buy was Netflix: 28,445,060 shares worth $179M.
- PFM Health Sciences added most to Rite Aid Corporation in Q2 2014, an estimated $221M increase.
- PFM Health Sciences's biggest Q2 2014 reduction was Alphabet (Google) Class C, cutting an estimated $230M.
- PFM Health Sciences fully exited iShares MSCI Emerging Markets ETF in Q2 2014, selling an estimated $439M.
- PFM Health Sciences's ten largest holdings make up 43% of its $5B portfolio in Q2 2014.
- PFM Health Sciences opened 18 new positions and closed 27 in Q2 2014.
- PFM Health Sciences's portfolio value fell 9.3% quarter-over-quarter to $5B.
Based on PFM Health Sciences's 13F filing for Q2 2014, filed 14 Aug 2014.